Young-Jo Song

Dr. Young-Jo Song


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2025 in Toxins
Verified
Journal Article
Open access
PDF file
CYChi Ho Yu
Chi Ho Yu
YSYoung-Jo Song
Young-Jo Song
DSDong Hyun Song
Dong Hyun Song
HJHAE EUN JOE
HAE EUN JOE
CKChanghwan Kim
Changhwan Kim
GHGyeunghaeng Hur
Gyeunghaeng Hur
Botulinum neurotoxins (BoNTs) are the most potent toxins on Earth and are classified as Category A biological agents. BoNTs lead to paralysis in humans and cause botulism. Antibody therapeutics can effectively treat toxin-mediated infectious diseases. In this study, we generated a pharmaceutical humanized monoclonal antibody (HZ45 mAb) to prevent or treat botulism. HZ45 binds to the heavy chain receptor (HCR) domain of the toxin, preventing the toxin from entering the cell. The mAb was produced using hybridoma technology and phage display. We evaluated HZ45 mAb for the neutralization of BoNT serotype A (BoNT/A) in mice and rabbits. The survival results showed that pretreatment with HZ45 mAb provided 100% protection at a dose of 0.1 mg per mouse against a maximum of 100 LD50 of BoNT/A. To assess the therapeutic efficacy of HZ45 mAb in New Zealand white rabbits (NZWs), a 5 mg dose was administered 4 or 8 h after challenge with 10 LD50. The results indicated that 5 mg of HZ45 could treat the NZWs within 8 h after exposure to 10 LD50 botulinum. Consequently, in an in vivo context, including mice and rabbits, HZ45 mAb could protect against botulinum type A intoxication.

29 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
HYHyeongseok Yun
Hyeongseok Yun
HJHAE EUN JOE
HAE EUN JOE
DSDong Hyun Song
Dong Hyun Song
YSYoung-Jo Song
Young-Jo Song
SHSunghyun Hong
Sunghyun Hong
CYChi Ho Yu
Chi Ho Yu
Background: Ricin, a toxin extracted from the seeds of Ricinus communis, is classified as a ribosome-inactivating protein. The A-subunit of ricin shows RNA N-glycosidase activity that cleaves ribosomal RNA (rRNA) and exhibits toxicity by inhibiting protein synthesis and inducing vascular leak syndrome. Methods: In this study, we created a truncated version of the previously developed R51 ricin vaccine (RTA 1-194 D75C Y80C) through in silico analysis. Results: The resulting R51-3 vaccine showed a more-than-six-fold increase in soluble protein expression when compared to R51, with over 85% solubility. In a pilot toxicity test, no toxicity was observed in hematological and biochemical parameters in BALB/c mice and New Zealand white rabbits following five repeated administrations of R51-3. Furthermore, R51-3 successfully protected mice and rabbits from a 20 × LD50 ricin challenge after three intramuscular injections spaced 2 weeks apart. Similarly, monkeys that received three injections of R51-3 survived a 60 µg/kg ricin challenge. Conclusions: These findings support R51-3 as a promising candidate antigen for ricin vaccine development.

5 June 2021 in Journal of the Korea Institute of Military Science and Technology
Verified
Journal Article
Open access
PDF file
YSYoung-Jo Song
Young-Jo Song
CYChi Ho Yu
Chi Ho Yu
SGSe Hun Gu
Se Hun Gu
GHGyeung Haeng Hur
Gyeung Haeng Hur
SJSeong Tae Jeong
Seong Tae Jeong

27 September 2025 in Gels
Verified
Journal Article
Open access
PDF file
JHJi-Hwan Ha
Ji-Hwan Ha
SJSohee Jeon
Sohee Jeon
YLYunwoo Lee¹
Yunwoo Lee¹
SHSoon Hyoung Hwang
Soon Hyoung Hwang
BKByung-Ho Kang
Byung-Ho Kang
JJJun-ho Jeong
Jun-ho Jeong
Antibodies are indispensable for protection against biological toxins and pathogens, yet their conventional liquid formulations impose severe constraints, including dosing inaccuracy caused by residual fluid remaining in the syringe and limited user convenience such as pain caused by fluid-induced tissue distension and nerve stimulation as well as instability in ambient temperature, and the requirement for low-temperature storage and logistics. These limitations critically impair rapid deployment during golden hour following acute exposure. Here, we report an antibody-integrated solid-to-gel microfilm—demonstrated with a 100 µg anti-BoNT/A dose—jet-printed and low-temperature dried directly onto metal needles for consistent, on-demand use. Upon intradermal insertion, the microfilm fully dissolves within 5 min, driven by hydration-induced swelling of a hyaluronic acid (HA) support layer and rapid release of the antibody. Time-resolved microscopy and UV–vis analysis showed a decrease in residual solid from 2.34 mm3 to 0 over 300 s, with a concomitant rise at 187 nm indicative of complete dissolution. The solid formulation maintained ambient-temperature stability for 3–6 months with pharmacokinetics comparable to conventional subcutaneous liquid injections. In a lethal BoNT/A challenge, treated mice achieved 100% survival for 12 days, whereas controls succumbed within 16 h.